医药生物技术及生物技术药物（三）——工程化抗体药物的现状及发展趋势
被引量：2
摘要
抗体药物始于免疫血清疗法，经历了多克隆抗体、单克隆抗体、工程化抗体等100多年的发展历程，现已步入成熟。目前已批准的30多种抗体药物取得了显著的临床疗效，其销售额已占全部生物药销售额的40％。全球正在进行Ⅰ、Ⅱ、Ⅲ期临床试验的抗体药物有270多种，抗体全人化、抗体高效化、抗体小型化、抗体融合蛋白等成为发展趋势。
出处
《中国医药技术经济与管理》
2009年第12期65-72,共8页
China Pharmaceutical Technology Economics & Management
参考文献9
-
1Sigrid R Ruuls, Jeroen JL Bueren, Jan GJ Winkel, et al. Novel human antibody therapeutics: The age of the Umabs. Biotechnol J, 2008, 3:1157-1171.
-
2Zhou JX, Tressel T, Yang XM, et al.lmplementation of advanced technologies in commercial monocIonal antibody production. Biotechnol J, 2008, 3:1185-1200.
-
3Benjamin Leader, Quentin J Baca and David E Golan. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov, 2008, 7:21-39.
-
4Perreault S and Burzynski J. Romiplostim: A novel bhrombopoiesis-stimulating agent. Am J Health-Syst Pharm, 2009, 66:817-824.
-
5Biotechnology Medicines in Development. Pharmaceutical Research and Manufacturers of America Report, 2000-2008. www.phrma.org.
-
6Amgen 2008 Annual Report and Rnancial Summary. February 6, 2009.
-
7http://www.amgen.com.
-
8Genentech 2008 Annual Report. February 20, 2009.
-
9http://www.gene.com/gene/index.jsp.
同被引文献25
-
1Pharmaceutical Research and Manufacturers of America. 2008 Biotechnology Medicines in Development. [2009-06-07]. http://www phrma.org/medicines in development_for_biotechnology.
-
21MS Health. IMS 2009 pharmaceutical market forecast: new reality for 2009 pharmaceutical market. (2008-10-02)[2009-07-01]. http:// www.eyeforpharma.com/forecastingusa08/presentations/DianaConmy. pdf.
-
3Steinberg FM, Raso J. Biotech pharmaceuticals and biotherapy: an overview. J Pharm Pharm Sci, 1998, 1(2):48-59.
-
4Pavlou AK, Reichert JM. Recombinant protein therapeutics--success rates, market trends and values to 2010. Nat Biotechnol, 2004, 22(12): 1513-1519.
-
51MS Health. Leading products by global pharmaceutical sales, 2006. (2007-05-20)[2009-03-11]. http://www.imshealth.com/imshealth.Global/Content/StaficFile/Top_Line_Data/Leading%20Products%20by%20G lobal%20Pharmaceutical%20Sales%202006.pdf.
-
6Amgen Inc. Amgen 2008 annual report and financial summary. (2009- 02-06)[2009-07-01]. http://www.amgen.com/pdfs/investors/Investors_ 2008_AnnualReport.pdf.
-
7Roche Ltd. Roche Finance Report 2008. (2009-01-29)[2009-07-01]. http://www.roche.com/investors/annual_reports.htm.
-
8Dingerraann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J, 2008, 3(1):90-97.
-
9Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov, 2008, 7(1):21- 39.
-
10Lanthier ML, Behrman R, Nardineni C. Economics issues with follow-on protein products. Nat Rev Drug Discov, 2008, 7(9):733- 737.
引证文献2
-
1朱迅.蛋白质药物的功能分类及发展趋势[J].中国医药生物技术,2010,5(1):6-11. 被引量：3
-
2翁志兵,王鹏红,赵力,夏松,金坚,朱祯平,李华钟.层析填料中顽固色素去除的新方法研究[J].食品与生物技术学报,2022,41(2):106-111.
二级引证文献3
-
1何添文,索朗斯珠,赵晓玲,旦巴次仁.藏仔猪脾脑蛋白水解复合物的制备及临床应用[J].畜牧与饲料科学,2010,31(11):4-5. 被引量：1
-
2万谦羽,唐海洲,李慧菁,毛雪,张坤.蛋白质吸附用静电纺丝纳米纤维材料研究进展[J].合成纤维工业,2023,46(5):61-65. 被引量：1
-
3万谦羽,唐海洲,杨赛迪,白莹,毛雪,张坤.“纳米沟壑”状PVDF多孔纳米纤维蛋白质吸附性能研究[J].纺织科学与工程学报,2024,41(2):37-41.
-
1金丹,裴国献.组织工程学研究现状及发展趋势[J].中国矫形外科杂志,2000,7(5):482-484. 被引量：11
-
2周开遗,王明举.国内外人工晶体的生产现状及发展趋势[J].实用眼科杂志,1992,10(9):514-517. 被引量：4
-
3钟化,胡圣榆.生物药物[J].国外药讯,1993(10):13-15. 被引量：1
-
4钟信.生物药物[J].国外药讯,1991,0(11):14-14.
-
5生物药的“黄金级”标准品[J].经济导报（医药技术）,2008(1):36-39.
-
6胡宝成.重组抗体工程及其在肿瘤靶向及癌症治疗中的应用[J].生物技术通讯,2001,12(3):226-232.
-
7苗向阳.基因工程抗体的研究进展[J].中国畜牧兽医,2003,30(4):29-31. 被引量：4
-
8李应全,厉保秋,等.rhIL—11对化疗猴血小板减少症的防治研究[J].中国药理学会通讯,2000,17(4):9-10.
-
9饶新华.未来的器官工厂[J].世界科学,1995,17(2):22-25.
-
10夏旭,王伟.白细胞介素15的研究近况[J].国外医学（免疫学分册）,1996,19(1):30-33.
